Last reviewed · How we verify
SHR6390 Tablets
SHR6390 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.
SHR6390 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | SHR6390 Tablets |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Sodium-activated potassium channel inhibitor |
| Target | Nav1.5 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting Nav1.5, SHR6390 is expected to reduce the risk of atrial fibrillation and its associated complications. This is achieved by modulating the electrical activity in the heart, thereby preventing the irregular heart rhythms associated with atrial fibrillation.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
- Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) (PHASE2)
- Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects (PHASE1)
- Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer (PHASE2)
- Study of SHR6390 in Renal Insufficiency and Healthy Subjects (PHASE1)
- A Trial of SHR6390 in Healthy Caucasian Volunteers (PHASE1)
- A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults (PHASE1)
- A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers (PHASE1)
- Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |